Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SYS6002

Phase 3Small molecule

CCSPC Megalith Biopharmaceutical Co.,Ltd.

SYS6002 is one of 95 small molecule programs targeting Cervical Cancer. It is currently in Phase 3.

3

Indications

4

Total Trials

4

Active Trials

94

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical CancerNot yet recruiting

Advanced Solid TumorsRecruiting

HNSCCNot yet recruiting

Cervical CancerPhase 3

Not yet recruiting

Advanced Solid TumorsPhase 2

Recruiting

HNSCCPhase 2

Not yet recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Yervoy

Bristol-Myers Squibb

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Afinitor

Alimta

Trodelvy

Myrbetriq

Inlyta

PPrism Pharmaceuticals

PENPULIMAB KCQX

Navmi

SSummit Therapeutics

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Cervical Cancer

NCT07230626

Phase 2Not yet recruiting

HNSCC

NCT06989671

Q4 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07241936

Phase 2Not yet recruiting

Urothelial Carcinoma

NCT07374549

Clinical

Trials by Indication[1]

HNSCC1 trial

SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT06989671·430 enrolled

Advanced Solid Tumors1 trial

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT07241936·444 enrolled

Urothelial Carcinoma1 trial

SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT07374549·100 enrolled

Cervical Cancer1 trial

SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 3·NCT07230626·412 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SYS6002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYS6002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYS6002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Megalith Biopharmaceutical Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Megalith Biopharmaceutical Co.,Ltd.

Related News